Table 1 Characteristics of diabetic patients undergoing SFA stenting
|  | +TXD N = 24 | -TZD N = 114 | P-value |
|---|---|---|---|
Age | 64.46 | 69.57 | 0.06 |
Male | 79.17% | 54.39% | 0.03 |
HTN | 91.67% | 88.60% | 0.66 |
HLD | 79.17% | 81.58% | 0.78 |
CAD | 54.17% | 54.39% | 0.98 |
CKD | 13.39% | 14.91% | 0.76 |
COPD | 4.17% | 11.93% | 0.26 |
Current smoker | 12.50% | 22.81% | 0.26 |
Statin | 62.50% | 69.03% | 0.53 |
ASA | 78.26% | 79.44% | 0.9 |
Plavix | 39.13% | 51.40% | 0.29 |
Cilostazol | 8.70% | 14.02% | 0.49 |
Insulin | 50.00% | 64.04% | 0.24 |
Metformin | 37.50% | 35.09% | 0.82 |
Sulfonylurea | 29.17% | 37.72% | 0.49 |
CLI | 33.33% | 62.2/8% | 0.01 |
TASC A or B | 100% | 76.32% | 0.01 |
Preop toe pressure | 52.5 | 40.95 | 0.18 |
3 Vessel outflow | 41.67% | 35.09% | 0.54 |